Abstract
371P Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have